{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:21Z","timestamp":1787009061814,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"name":"US Department of Veterans Affairs Health Services Research"},{"name":"Development Service of the VHA Office of Research and Development"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Prediction models using statistical or machine learning (ML) approaches can enhance clinical decision support tools. Infliximab (IFX), a biologic with a newly introduced biosimilar for Crohn\u2019s disease (CD) and ulcerative colitis (UC), presents an opportunity to evaluate these tools at time of biosimilar switch to predict disease flares. This study sought to evaluate real-world safety and effectiveness of nonmedical IFX biosimilar switch in a national US cohort of CD and UC patients, and to develop and compare interpretable models for predicting adverse clinical events among patients on maintenance IFX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used administrative and clinical data from the National Veterans Health Administration Corporate Data Warehouse. It included 2529 Veterans with CD or UC on maintenance IFX (2017-2020), either continuing originator IFX or switching to a biosimilar. The primary outcome was disease-related flare. Classification and survival models were developed using traditional and ML methods and assessed via receiver operating characteristic curve, precision\u2013recall curve, and decision curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2529 Veterans with CD or UC, biosimilar switch had low predictive importance across survival models. Objective laboratory-related information yielded the highest validation. Random forest+ (RF+) outperformed all other statistical and ML models. Prior flares and total health-care encounters were the 2 most important predictors, while hemoglobin was the top laboratory predictor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prediction models, particularly RF+, may aid in optimizing biologic therapy for CD and UC by identifying patients at higher risk of flare following a biosimilar switch.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jamiaopen\/ooaf162","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:22:30Z","timestamp":1763731350000},"source":"Crossref","is-referenced-by-count":2,"title":["Using machine learning algorithms to optimize treatment with high-cost biologics in a national cohort of patients with inflammatory bowel disease"],"prefix":"10.1093","volume":"8","author":[{"given":"Jason K","family":"Hou","sequence":"first","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Baylor College of Medicine , Houston, TX 77030,","place":["United States"]},{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center , Houston, TX 77030,","place":["United States"]},{"name":"Section of Health Services Research, Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany M","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Michigan , Ann Arbor, MI, 48109,","place":["United States"]},{"name":"Department of Applied and Computational Mathematics and Statistics, University of Notre Dame , Notre Dame, IN 46556,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhada","family":"Sansgiry","sequence":"additional","affiliation":[{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center , Houston, TX 77030,","place":["United States"]},{"name":"Section of Health Services Research, Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Van","sequence":"additional","affiliation":[{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System , Ann Arbor, MI 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Richardson","sequence":"additional","affiliation":[{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center , Houston, TX 77030,","place":["United States"]},{"name":"Section of Health Services Research, Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Codey","family":"Pham","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Medication Safety , Hines, IN, 60141,","place":["United States"]},{"name":"United Stated Department of Veterans Affairs VA Pharmacy Benefits Management Services, Washington , DC, 20422,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A","family":"Baker","sequence":"additional","affiliation":[{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System , Ann Arbor, MI 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Michigan , Ann Arbor, MI, 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar K","family":"Waljee","sequence":"additional","affiliation":[{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System , Ann Arbor, MI 48109,","place":["United States"]},{"name":"Center for Global Health and Equity, University of Michigan , Ann Arbor, 48109,","place":["United States"]},{"name":"Department of Learning Health Sciences, University of Michigan , Ann Arbor, MI, 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2025120600351713500_ooaf162-B1","doi-asserted-by":"crossref","first-page":"e0145087","DOI":"10.1371\/journal.pone.0145087","article-title":"A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases","volume":"10","author":"Huoponen","year":"2015","journal-title":"PLoS One"},{"key":"2025120600351713500_ooaf162-B2","first-page":"s51","article-title":"Report: economic implications of inflammatory bowel disease and its management","volume":"22","author":"Mehta","year":"2016","journal-title":"Am J Manag Care"},{"key":"2025120600351713500_ooaf162-B3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jpn3.12153","article-title":"Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children\/young adults with inflammatory bowel disease","volume":"78","author":"McNicol","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025120600351713500_ooaf162-B4","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.2147\/CMAR.S164201","article-title":"The role of biosimilars in value-based oncology care","volume":"10","author":"Patel","year":"2018","journal-title":"Cancer Manag Res"},{"key":"2025120600351713500_ooaf162-B5","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"key":"2025120600351713500_ooaf162-B6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","article-title":"Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance","volume":"85","author":"Scherlinger","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2025120600351713500_ooaf162-B7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40259-016-0202-5","article-title":"Rheumatologists\u2019 perceptions of biosimilar medicines prescription: findings from a French web-based survey","volume":"30","author":"Beck","year":"2016","journal-title":"BioDrugs"},{"key":"2025120600351713500_ooaf162-B8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1186\/s12913-024-11570-3","article-title":"Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease","volume":"24","author":"Ryan","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2025120600351713500_ooaf162-B9","doi-asserted-by":"crossref","first-page":"E109","DOI":"10.9778\/cmajo.20200319","article-title":"Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study","volume":"10","author":"Fisher","year":"2022","journal-title":"CMAJ Open"},{"key":"2025120600351713500_ooaf162-B10","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1007\/s10620-014-3174-7","article-title":"Accuracy of diagnostic codes for identifying patients with ulcerative colitis and Crohn\u2019s disease in the Veterans Affairs Health Care System","volume":"59","author":"Hou","year":"2014","journal-title":"Dig Dis Sci"},{"key":"2025120600351713500_ooaf162-B11","doi-asserted-by":"crossref","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ."},{"key":"2025120600351713500_ooaf162-B12","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.1901326117","article-title":"Veridical data science","volume":"117","author":"Yu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025120600351713500_ooaf162-B13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the Lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"2025120600351713500_ooaf162-B14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/00401706.2000.10485983","article-title":"Ridge regression: biased estimation for nonorthogonal problems","volume":"42","author":"Hoerl","year":"2000","journal-title":"Technometrics"},{"key":"2025120600351713500_ooaf162-B15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","article-title":"Regularization and variable selection via the elastic net","volume":"67","author":"Zou","year":"2005","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"2025120600351713500_ooaf162-B16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1214\/aos\/1013203451","article-title":"Greedy function approximation: a gradient boosting machine","volume":"29","author":"Friedman","year":"2001","journal-title":"Ann Statist"},{"key":"2025120600351713500_ooaf162-B17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"2025120600351713500_ooaf162-B18","author":"Agarwal","year":"2023"},{"key":"2025120600351713500_ooaf162-B19","author":"Erickson","year":"2020"},{"key":"2025120600351713500_ooaf162-B20","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"2025120600351713500_ooaf162-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for Cox\u2019s proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J Stat Softw"},{"key":"2025120600351713500_ooaf162-B22","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1177\/09622802221111549","article-title":"Ensemble methods for survival function estimation with time-varying covariates","volume":"31","author":"Yao","year":"2022","journal-title":"Stat Methods Med Res"},{"key":"2025120600351713500_ooaf162-B23","volume-title":"Classification and Regression Trees","author":"Breiman","year":"1984","edition":"1st ed"},{"key":"2025120600351713500_ooaf162-B24","author":"Agarwal","year":"2023"},{"key":"2025120600351713500_ooaf162-B25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ibd\/izx007","article-title":"Predicting hospitalization and outpatient corticosteroid use in inflammatory bowel disease patients using machine learning","volume":"24","author":"Waljee","year":"2017","journal-title":"Inflamm Bowel Dis"}],"container-title":["JAMIA Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article-pdf\/8\/6\/ooaf162\/65780607\/ooaf162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article-pdf\/8\/6\/ooaf162\/65780607\/ooaf162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:35:23Z","timestamp":1764999323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamiaopen\/article\/doi\/10.1093\/jamiaopen\/ooaf162\/8371988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jamiaopen\/ooaf162","relation":{},"ISSN":["2574-2531"],"issn-type":[{"value":"2574-2531","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,3]]},"article-number":"ooaf162"}}